Tumor‐Derived Extracellular Vesicles in Plasma for Predicting Anti‐ PD ‐1 Antibody Efficacy in Non‐Small Cell Lung Cancer
Cancer Science · 2026-08 · 117 (8) · 2152-2165
DOI: 10.1111/cas.70412 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 24.05.2026. Verfasst von Tomonari Kinoshita und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Thoracic Surgery, Department of Surgery, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Extracellular Vesicles, Programmed Cell Death 1 Receptor. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development, Grants-in-aid for Scientific Research.
Abstract (Originalsprache)
Liquid biopsy is a promising biomarker for cancer detection and prediction of therapy responses. In this study, we developed new antibody‐based sandwich assays to measure three extracellular vesicle (EV) subsets that express cell surface vimentin (CSV) and co‐express epithelial cell adhesion molecule (EpCAM) or PD‐L1 in plasma. Fifty‐seven non‐small cell lung cancer (NSCLC) patients who underwent complete resection and 89 stage IV NSCLC patients who received anti‐PD‐1 antibody were enrolled. Correlations between the plasma EV subsets at baseline and various clinicopathological factors were evaluated. Plasma EpCAM/CSV‐EV levels were significantly higher in stage I NSCLC patients compared to healthy donors, suggesting this may be a valuable biomarker for detecting early‐stage NSCLC. High plasma CSV/CSV‐EV levels at baseline were significantly correlated with a poor prognosis after treatment, both in the surgery cohort and the anti‐PD‐1 antibody cohort, which suggests that this may be useful for predicting the post‐treatment prognosis in NSCLC patients. High plasma CSV/PD‐L1‐EV levels at baseline were significantly correlated with poor postoperative prognosis. However, high plasma CSV/PD‐L1‐EV levels at baseline were significantly correlated with a favorable clinical response and prognosis following anti‐PD‐1 antibody treatment in stage IV NSCLC. Therefore, plasma CSV‐related EV subsets at baseline may be attractive biomarkers for early cancer detection (EpCAM/CSV), prediction of postoperative prognosis (CSV/CSV), and prediction of clinical responses and prognosis after anti‐PD‐1 antibody therapy (CSV/PD‐L1). These EV subsets can be easily measured repetitively at appropriate timing. These novel liquid biopsies may be additional and complementary diagnostic biomarkers for NSCLC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of General Thoracic Surgery, Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
- Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan.
- Department of Immunology, School of Medicine, International University of Health and Welfare, Chiba, Japan.
- JSR-Keio University Medical and Chemical Innovation Center (JKiC), Tokyo, Japan.
- Division of Pathology, Keio University School of Medicine, Tokyo, Japan.
- Department of Pathology, International University of Health and Welfare, Narita Hospital, Chiba, Japan.
ORCID-Profile: Tomonori Yaguchi, Yutaka Kawakami
Förderung
- Japan Agency for Medical Research and Development
- Grants-in-aid for Scientific Research
Zitieren
APA
Kinoshita, T., Ohta, S., Wakui, S., Maeda, C., Hayashi, Y., Misawa, A., Satomi, R., Ikemura, S., Soejima, K., Yaguchi, T., Maruyama, S., Kagamu, H., & Kawakami, Y. (2026). Tumor‐Derived Extracellular Vesicles in Plasma for Predicting Anti‐ PD ‐1 Antibody Efficacy in Non‐Small Cell Lung Cancer. Cancer Science, 117(8), 2152-2165. https://doi.org/10.1111/cas.70412
Vancouver
Kinoshita T, Ohta S, Wakui S, Maeda C, Hayashi Y, Misawa A, et al. Tumor‐Derived Extracellular Vesicles in Plasma for Predicting Anti‐ PD ‐1 Antibody Efficacy in Non‐Small Cell Lung Cancer. Cancer Science. 2026;117(8):2152-2165. doi:10.1111/cas.70412
BibTeX
@article{Kinoshita2026,
author = {Kinoshita, Tomonari and Ohta, Shigeki and Wakui, Seiki and Maeda, Chihaya and Hayashi, Yuichiro and Misawa, Aya and Satomi, Ryosuke and Ikemura, Shinnosuke and Soejima, Kenzo and Yaguchi, Tomonori and Maruyama, Shotaro and Kagamu, Hiroshi and Kawakami, Yutaka},
title = {Tumor‐Derived Extracellular Vesicles in Plasma for Predicting Anti‐ PD ‐1 Antibody Efficacy in Non‐Small Cell Lung Cancer},
journal = {Cancer Science},
year = {2026},
volume = {117},
number = {8},
pages = {2152--2165},
doi = {10.1111/cas.70412}
}
EUVIMED